| Name | Title | Contact Details |
|---|
OMICS Group Inc is a Henderson, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Arcutis was founded in 2016 to address significant unmet needs in medical dermatology. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our team`s unique experience and demonstrated expertise to identify, develop and commercialize best-in-class molecules against validated targets, we will be able to develop differentiated products in less time, at lower cost, and at substantially lower risk than other approaches. Arcutis` combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector.
Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women`s health diseases and other endocrine-related disorders. Myovant`s lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant is in the process of initiating five international Phase 3 clinical trials for relugolix, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis-associated pain, and one in men with advanced prostate cancer. Myovant is simultaneously developing MVT-602, an analog of kisspeptin, for the treatment of female infertility as part of assisted reproduction. Over time, the company intends to expand its development pipeline to include other potential treatments for women`s health and endocrine-related disorders.
Cerecor is building a global biopharmaceutical enterprise with a near-term pipeline of six clinical programs. All of our pipeline products have unique and novel mechanisms of action with the potential to be first-in-class compounds.
Amlan International is the animal health business of Oil-Dri® Corporation of America, a leader in sorbent mineral technology. Amlan leverages Oil-Dri`s 80-plus years of mineral science expertise to develop proprietary, mineral-based feed additives that support optimal intestinal health while adding value for animal protein producers. The core of our feed additives is our natural mineral ingredient that contains high-capacity opal-CT lepispheres and undergoes proprietary thermal processing specifically tailored for each product. We also create synergistic blends of our mineral with other feed ingredients that further support normal gut function and digestive processes. Oil-Dri and the single-source mineral used in Amlan products are based in the USA, and because Amlan and Oil-Dri are vertically integrated, we control the quality, reliability, and safety of the mineral — from mine to feed bag. We do this by following sustainable mining practices and through the use of natural ingredients in our products. Our mineral-based feed additives meet the demands for cleaner food while reducing the inputs needed to raise production animals, helping to decrease the cost and environmental impact of poultry and livestock production. Leading integrators and producers worldwide trust our products to support animal intestinal health and add value to their operations. You can, too.